Trevi Therapeutics to Participate in Upcoming April Investor Conferences

NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be participating in the following investor conferences in April.

24th Annual Needham Virtual Healthcare Conference
April 7-10, 2025
Corporate Presentation: April 7, 11:00-11:40 a.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, CCO
Register here to watch the live presentation.

Jones Healthcare and Technology Innovation Conference
April 8-9, 2025, Las Vegas, Nevada
Corporate Presentation: April 9, 11:00-11:20 a.m. PT
Trevi Presenter: Jennifer Good, President and CEO
Presentation available to in-person attendees.

Piper Sandler Spring Biopharma Symposium
April 16-17, 2025, Boston, Massachusetts
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, CDO

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is the first and only therapy in clinical development to show a statistically significant reduction in chronic cough across patients with both IPF and RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.  

Chronic cough is a highly prevalent condition in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. 

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
[email protected]

Media Contact
Rosalia Scampoli
914-815-1465
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences-302419110.html

SOURCE Trevi Therapeutics, Inc.